, Tracking Stock Market Picks
Enter Symbol:
Biovail Corporation (BVF) [hlAlert]

up 922.63 %

Biovail Corporation (BVF) rated Buy with price target $30 by Deutsche Bank

Posted on: Wednesday,  Sep 8, 2010  2:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Valeant Pharmaceuticals International Inc (NYSE: VRX) on 09/08/2010. Previously Deutsche Bank rated Buy Valeant Pharmaceuticals International Inc (NYSE: VRX)
on 08/12/2010., when the stock price was $22.97. Since then, Valeant Pharmaceuticals International Inc has gained 922.64% as of 01/06/2016's recent price of $234.90.
If you would have followed the previous Deutsche Bank's recommendation on VRX, you would have gained 922.63% of your investment in 1973 days.

Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. The Company has various research and development, clinical research, manufacturing and commercial operations located in Barbados, Canada, the United States and Puerto Rico. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. On September 16, 2008, Biovail acquired Prestwick Pharmaceuticals, Inc.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy